Advent of Bispecific Antibodies for Relapsed/Refractory Follicular Lymphoma

Video

Expert perspectives on the advent of bispecific antibody therapy in relapsed/refractory follicular lymphoma, centered on data and experience with several novel agents.

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content